Vireo Growth Closes PharmaCann Colorado Retail Acquisition

Vireo Growth Inc. said on August 7, 2026 that it has received all required regulatory approvals and completed its acquisition of certain Colorado retail assets from PharmaCann Inc., closing a deal the two companies first signed in December 2025.

Total consideration was approximately $49.0 million, paid in Vireo subordinate voting shares plus the assumption of certain liabilities, according to the company’s completion announcement. The final share figure reflects customary closing adjustments for inventory levels, trade payables, and other items set out in the Asset Purchase Agreement. The acquired business consists of 17 dispensaries, bringing Vireo’s Colorado retail footprint to 56 operational locations.

“Receiving final regulatory approval and completing this transaction marks another important milestone in executing our disciplined acquisition strategy,” said Vireo Chief Executive Officer John Mazarakis. “Equally important, it validates the operating model we have built for integrating acquired businesses.”

A Deal That Ran Through a Management Agreement First

The closing completes a two-step structure Vireo has used to take control of the assets before the formal transfer. Vireo and its subsidiary Vireo Health, Inc. signed the Asset Purchase Agreement on December 16, 2025, along with a Management Services Agreement under which a Vireo affiliate would operate the PharmaCann Colorado stores until closing.

That management agreement went into effect on March 22, 2026, according to a company exhibit filed with the SEC. As part of that step, Vireo delivered 90,740,741 subordinate voting shares from treasury into escrow with Odyssey Trust Company, to be released on closing. The August 7 completion ends the management agreement and folds the acquired operations fully into Vireo’s existing Colorado platform.

Mazarakis said the integration work is already underway. “Over the past several months, our team has already made meaningful progress improving operations across the PharmaCann Colorado assets while continuing to invest in future growth,” he said, citing a strengthened leadership team, expanded product assortment, and new operating systems.

How the Final Terms Compare to the December Agreement

The headline consideration is unchanged from the original agreement. When the deal was signed on December 16, 2025, Vireo said total consideration would be approximately $49.0 million, payable in subordinate voting shares at closing plus the assumption of certain liabilities, per its definitive-agreement release.

What moved is the dispensary count and the timeline. The December announcement projected the transaction would lift Vireo to 41 total active Colorado dispensaries and close in the first half of calendar 2026. The completed transaction instead brings Vireo to 56 operational locations, and it closed in August rather than the first half. The December release also noted the share consideration would be subject to adjustment based on inventory and trade payables, which is the mechanism behind the “customary closing adjustments” language in the completion notice.

• Total consideration: approximately $49.0 million
• Consideration structure: Vireo subordinate voting shares plus assumed liabilities
• Dispensaries acquired: 17
• Vireo Colorado locations after closing: 56
• Shares placed in escrow in March 2026: 90,740,741
• Asset Purchase Agreement signed: December 16, 2025
• Management Services Agreement effective: March 22, 2026

Vireo, founded in 2014 as a medical cannabis company, has been assembling its national footprint through a string of acquisitions, and the PharmaCann Colorado assets extend a strategy the company describes as accretive M&A. The company has said it will continue initiatives focused on operational execution, margin expansion, and organic growth across the integrated Colorado platform.